ETCTN NORM: Nodular Lymphocyte-predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial with Either Rituximab or Mosunetuzumab Adult CIRB - Early Phase Emphasis Active Available to Open